Mallinckrodt Public Limited Company ROA 2012-2018 | MNK

Current and historical return on assets (ROA) values for Mallinckrodt Public Limited Company (MNK) over the last 10 years. Return on assets can be defined as an indicator of how profitable a company is relative to its total assets. Calculated by dividing a company's operating earnings by its total assets. Mallinckrodt Public Limited Company ROA for the three months ending September 30, 2018 was 4.12%.
Mallinckrodt Public Limited Company ROA - Return on Assets Historical Data
Date TTM Net Income Total Assets Return on Assets
2018-09-30 $1.72B $14.91B 11.32%
2018-06-30 $1.67B $15.05B 11.04%
2018-03-31 $1.72B $15.52B 11.44%
2017-12-31 $2.14B $15.34B 14.39%
2017-09-30 $0.53B $14.61B 3.55%
2017-06-30 $0.58B $14.62B 5.17%
2017-03-31 $0.71B $14.78B 6.23%
2016-12-31 $0.43B $15.21B 3.68%
2016-09-30 $0.64B $0.00B 5.38%
2016-06-30 $0.53B $15.83B 3.29%
2016-03-31 $0.39B $15.90B 2.45%
2015-12-31 $0.37B $16.04B 2.45%
2015-09-30 $0.25B $16.40B 1.76%
2015-06-30 $-0.10B $14.88B -0.77%
2015-03-31 $-0.18B $12.81B -1.68%
2014-12-31 $-0.27B $12.77B -2.97%
2014-09-30 $-0.32B $12.87B -4.66%
2014-06-30 $0.07B $5.42B 1.51%
2014-03-31 $0.06B $5.46B 1.61%
2013-12-31 $0.09B $3.57B 3.30%
2013-09-30 $0.06B $3.56B 3.44%
2013-06-30 $0.05B $3.31B 3.30%
2013-03-31 $0.11B $0.00B 15.58%
2012-12-31 $0.08B $0.00B 10.85%
Sector Industry Market Cap Revenue
Medical Medical - Generic Drugs $2.333B $3.222B
Mallinckrodt Plc. is engaged in pharmaceuticals business. It develops, manufactures, markets and distributes specialty pharmaceutical products and medical imaging agents. The company's Specialty Pharmaceuticals segment includes branded and generic drugs and Medical Imaging segment includes contrast media and nuclear imaging agents. Mallinckrodt Plc. is based in Dublin, Ireland.
Stock Name Country Market Cap PE Ratio
Allergan (AGN) Ireland $51.740B 8.88
Teva Pharmaceutical Industries (TEVA) Israel $22.137B 6.78
Mylan (MYL) United Kingdom $17.485B 7.20
Bausch Health Cos (BHC) Canada $7.957B 5.76
Dr Reddy's Laboratories (RDY) India $6.053B 24.17
Supernus Pharmaceuticals (SUPN) United States $2.207B 20.91
Amphastar Pharmaceuticals (AMPH) United States $0.925B 100.35
Akorn (AKRX) United States $0.848B 0.00
Homology Medicines (FIXX) United States $0.690B 0.00
Assembly Biosciences (ASMB) United States $0.620B 0.00
CymaBay Therapeutics (CBAY) United States $0.511B 0.00
Corium (CORI) United States $0.459B 0.00
Progenics Pharmaceuticals (PGNX) United States $0.428B 0.00
Voyager Therapeutics (VYGR) United States $0.378B 0.00
Adamas Pharmaceuticals (ADMS) United States $0.270B 0.00
Sol-Gel Technologies (SLGL) Israel $0.128B 0.00
Teligent (TLGT) United States $0.112B 0.00
Zynerba Pharmaceuticals (ZYNE) United States $0.085B 0.00
Aevi Genomic Medicine (GNMX) United States $0.067B 0.00
Aquinox Pharmaceuticals (AQXP) Canada $0.052B 0.00
Acasti Pharma (ACST) Canada $0.052B 0.00
Evoke Pharma (EVOK) United States $0.042B 0.00
Agile Therapeutics (AGRX) United States $0.030B 0.00
China Pharma Holdings (CPHI) China $0.014B 0.00
Pernix Therapeutics Holdings (PTX) United States $0.008B 0.00